Business
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/a65b2254e4fad33e9b06532c1096f80c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2K_jS0oItbqmH4M0dhn7Sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a65b2254e4fad33e9b06532c1096f80c","width":300,"height":103}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China ","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales ","length":285,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":441,"olType":false},{"type":"text","content":"Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, and along with its subsidiaries, hereafter referred to as “Dr. Reddy’s”), today announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.","length":716,"tagName":"p"},{"type":"text","content":"Efti is Immutep’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma.","len...